Please assess the completion status of the following clinical trial:

Trial Title: Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smokers or former smokers of at least 10 pack-years~* COPD demonstrated by forced spirometry with FEV1 \> 0,7 L, FEV1 post-BD \<60% and FEV1/FVC \< 70%~* Bronchodilator test performed at inclusion or no more than 6 months before inclusion should have been negative (increase in FEV1 \< 200 ml and 12%, 10 minutes after administration of 2 puffs of salbutamol~* Stable phase defined by clinical criteria of the attending investigator, but at least 6 weeks from the last exacerbation~* Informed consent~Exclusion Criteria:~* Patients receiving oral corticosteroids at any dose or another immunosuppressor~* Formal contraindication for sputum collection or impossibility to obtain a sample of sputum valid for analysis.~* Allergy to steroids or macrolides

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): standard of care
- 2 (Type: EXPERIMENTAL): azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
- 3 (Type: EXPERIMENTAL): inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).